Stock LSTA LISATA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Lisata Therapeutics, Inc.

Equities

LSTA

US1280583022

Market Closed - Nasdaq
Other stock markets
 02:00:00 01/05/2024 am IST 		5-day change 1st Jan Change
2.73 USD -0.73% Intraday chart for Lisata Therapeutics, Inc. +3.02% -.--%
23/04 Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer MT
23/04 Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
Sector Update: Health Care Stocks Higher in Afternoon Trading
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme
Lisata Therapeutics, Inc. Announces Completion of Enrollment in Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Lisata Therapeutics, Inc. Announces LSTA1 as A Treatment for Solid Tumor Cancers in Combination with Other Anti-Cancer Agents
Lisata Therapeutics, Inc. Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1
Lisata Therapeutics, Inc. Announces Outcome of Interim Futility Analysis for Its Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Lisata Therapeutics' LSTA1 Malignant Glioma Treatment Candidate Gets FDA Orphan Drug Label
Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors
Lisata Therapeutics Announces Enhancements to Ongoing Phase 2B Ascend Trial of LSTA1
Lisata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Lisata Therapeutics Announces Resignation of David Slack as President and Chief Business Officer
Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LSTA Stock
  4. News Lisata Therapeutics, Inc.
  5. Other languages